Sandeep Soni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sandeep Soni has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Thomas G. Gross
Division of Hematology/Oncology/BMT; Nationwide Children's Hospital and Department of Pediatrics; The Ohio State University; Columbus Ohio
2 shared publicationsAlexandra Cheerva
Division of Heme/Onc/BMT Kosair Children's Hospital University of Louisville Louisville KY USA
1 shared publicationAndromachi Scaradavou
Memorial Sloan-Kettering Cancer Center, Weill-Cornell School of Medicine; New York New York
1 shared publicationFarid Boulad
Memorial Sloan-Kettering Cancer Center, Weill-Cornell School of Medicine; New York New York
1 shared publicationHemalatha Rangarajan
Division of Hematology/Oncology/BMT; Nationwide Children's Hospital and Department of Pediatrics; The Ohio State University; Columbus Ohio
1 shared publicationJueeli Dahake
Department of Pediatrics; University of California, San Francisco School of Medicine; San Francisco California
1 shared publication
Latest Publications
- 7 May 2014
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 61 (9) , 1690-1694
Combined umbilical cord blood and bone marrow from HLA-identical sibling donors for hematopoietic stem cell transplantation in children with hemoglobinopathies
Background It is well established that umbilical cord blood and bone marrow are biologically different stem cell sources. Patients and Methods We analyzed the feasibility and outcome of hematopoietic stem cell transplantation (HSCT) in 13 children (median age 5.9 years) with hemoglobinopathies after the co- infusion of cord blood (CB) and bone marrow (BM) from the same human leucocyte antigen (HLA) identical sibling donor. We also compared outcomes of children with co-transplantation to outcomes in children with hemoglobinopathies who had received a BM (n = 21) or CB (n = 22) transplant alone. Results Compared to CB transplant (CBT) recipients, the co-transplant group had more rapid neutrophil (17 vs. 25 days, P = 0.013) and platelet (29 vs. 48 days, P = 0.009) recovery and less transplant related mortality. Patients who received a co-transplant had a lower incidence of ≥grade II acute (0% vs. 26.3%) and chronic (0% vs. 21%) graft versus host disease (GVHD) compared to BM transplant (BMT) recipients (P = 0.055 and 0.045, respectively). With a median follow-up of >60 months in each treatment group, the 5-year probability of event free survival (EFS) was 100% in the co-transplant group, 90% after BMT and 86% after CBT (P = 0.42). Conclusion Co-transplantation of CB and BM from HLA-identical sibling donors appears to be a feasible and effective strategy to further optimize outcomes of HSCT for hemoglobinopathies. Pediatr Blood Cancer 2014;61:1690–1694.
- 7 May 2014
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 61 (9) , 1690-1694
Combined umbilical cord blood and bone marrow from HLA-identical sibling donors for hematopoietic stem cell transplantation in children with hemoglobinopathies
Background It is well established that umbilical cord blood and bone marrow are biologically different stem cell sources. Patients and Methods We analyzed the feasibility and outcome of hematopoietic stem cell transplantation (HSCT) in 13 children (median age 5.9 years) with hemoglobinopathies after the co- infusion of cord blood (CB) and bone marrow (BM) from the same human leucocyte antigen (HLA) identical sibling donor. We also compared outcomes of children with co-transplantation to outcomes in children with hemoglobinopathies who had received a BM (n = 21) or CB (n = 22) transplant alone. Results Compared to CB transplant (CBT) recipients, the co-transplant group had more rapid neutrophil (17 vs. 25 days, P = 0.013) and platelet (29 vs. 48 days, P = 0.009) recovery and less transplant related mortality. Patients who received a co-transplant had a lower incidence of ≥grade II acute (0% vs. 26.3%) and chronic (0% vs. 21%) graft versus host disease (GVHD) compared to BM transplant (BMT) recipients (P = 0.055 and 0.045, respectively). With a median follow-up of >60 months in each treatment group, the 5-year probability of event free survival (EFS) was 100% in the co-transplant group, 90% after BMT and 86% after CBT (P = 0.42). Conclusion Co-transplantation of CB and BM from HLA-identical sibling donors appears to be a feasible and effective strategy to further optimize outcomes of HSCT for hemoglobinopathies. Pediatr Blood Cancer 2014;61:1690–1694.
- 17 April 2014
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 61 (9) , 1685-1689
Outcomes of matched sibling donor hematopoietic stem cell transplantation for severe sickle cell disease with myeloablative conditioning and intermediate-dose of rabbit anti-thymocyte globulin
Background Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative therapy for sickle cell disease (SCD) in children. Despite excellent outcomes of matched sibling donor (MSD) HSCT, there is still 5–10% chance of rejection and transplant related mortality (TRM) with 12–23% incidence of graft versus host disease (GVHD). We postulated that an intermediate dose of rabbit anti-thymocyte globulin (r-ATG, 10 mg/kg cumulative) would be effective in preventing both rejection and GVHD. Patients and Methods Fifteen patients, median age 5 (range 1.5–18) years, underwent MSD HSCT using busulfan (≥12.8 mg/kg with first dose pharmacokinetics), cyclophosphamide (total 200 mg/kg) and r-ATG. Bone marrow was the stem cell source; tacrolimus and methotrexate were given for GVHD prophylaxis. Results All patients achieved donor engraftment and there was no TRM. One patient rejected donor cells at 2 months post-transplant. Majority of the patients had high and sustained level of donor chimerism. None of the patients developed ≥Grade II GVHD. Incidence of CMV (10%) and EBV (9%) reactivations was low with rapid immune-reconstitution. Overall survival was 100% with event free survival of 93%. Conclusions Eliminating the risks of TRM and GVHD by optimizing the regimen may lead to further acceptance of HSCT for SCD. Pediatr Blood Cancer 2014;61:1685–1689.
- 17 April 2014
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 61 (9) , 1685-1689
Outcomes of matched sibling donor hematopoietic stem cell transplantation for severe sickle cell disease with myeloablative conditioning and intermediate-dose of rabbit anti-thymocyte globulin
Background Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative therapy for sickle cell disease (SCD) in children. Despite excellent outcomes of matched sibling donor (MSD) HSCT, there is still 5–10% chance of rejection and transplant related mortality (TRM) with 12–23% incidence of graft versus host disease (GVHD). We postulated that an intermediate dose of rabbit anti-thymocyte globulin (r-ATG, 10 mg/kg cumulative) would be effective in preventing both rejection and GVHD. Patients and Methods Fifteen patients, median age 5 (range 1.5–18) years, underwent MSD HSCT using busulfan (≥12.8 mg/kg with first dose pharmacokinetics), cyclophosphamide (total 200 mg/kg) and r-ATG. Bone marrow was the stem cell source; tacrolimus and methotrexate were given for GVHD prophylaxis. Results All patients achieved donor engraftment and there was no TRM. One patient rejected donor cells at 2 months post-transplant. Majority of the patients had high and sustained level of donor chimerism. None of the patients developed ≥Grade II GVHD. Incidence of CMV (10%) and EBV (9%) reactivations was low with rapid immune-reconstitution. Overall survival was 100% with event free survival of 93%. Conclusions Eliminating the risks of TRM and GVHD by optimizing the regimen may lead to further acceptance of HSCT for SCD. Pediatr Blood Cancer 2014;61:1685–1689.
- 16 December 2013
- Published by Wiley in Pediatric Transplantation
- Vol. 18 (2) , 217-220
Busulfan and melphalan as consolidation therapy with autologous peripheral blood stem cell transplantation following Children's Oncology Group (COG) induction platform for high‐risk neuroblastoma: Early results from a single institution
Bu‐Mel as preparative therapy prior to autologous stem cell rescue was recently shown to be superior to the conventional CEM regimen for HR NBL in Europe. There are no data available on the feasibility and toxicity of Bu‐Mel as consolidation therapy following the COG‐type induction regimens used in North America. We report early complications and outcomes of patients with HR NBL who received Bu‐Mel for consolidation following COG‐based induction. Retrospective analysis of all patients who had received Bu‐Mel as preparative regimen prior to stem cell rescue for HR NBL was carried out. Toxicity, outcomes, and any delays to receiving radiation or anti‐GD2 antibody therapy were analyzed. Six patients undergoing PBSCT had received Bu‐Mel. The treatment was well tolerated. Mucositis was the main toxicity; three patients had developed neutropenia fever and none developed pulmonary toxicity. One patient had developed moderate SOS that responded to conservative management. All patients were able to receive and tolerate post‐transplant local radiotherapy and ch.14.18 anti‐GD2 antibody therapy without any delays. All patients are alive with no disease recurrence. The Bu‐Mel regimen is well tolerated and is feasible post‐COG‐type induction platform.
- 16 December 2013
- Published by Wiley in Pediatric Transplantation
- Vol. 18 (2) , 217-220
Busulfan and melphalan as consolidation therapy with autologous peripheral blood stem cell transplantation following Children's Oncology Group (COG) induction platform for high‐risk neuroblastoma: Early results from a single institution
Bu‐Mel as preparative therapy prior to autologous stem cell rescue was recently shown to be superior to the conventional CEM regimen for HR NBL in Europe. There are no data available on the feasibility and toxicity of Bu‐Mel as consolidation therapy following the COG‐type induction regimens used in North America. We report early complications and outcomes of patients with HR NBL who received Bu‐Mel for consolidation following COG‐based induction. Retrospective analysis of all patients who had received Bu‐Mel as preparative regimen prior to stem cell rescue for HR NBL was carried out. Toxicity, outcomes, and any delays to receiving radiation or anti‐GD2 antibody therapy were analyzed. Six patients undergoing PBSCT had received Bu‐Mel. The treatment was well tolerated. Mucositis was the main toxicity; three patients had developed neutropenia fever and none developed pulmonary toxicity. One patient had developed moderate SOS that responded to conservative management. All patients were able to receive and tolerate post‐transplant local radiotherapy and ch.14.18 anti‐GD2 antibody therapy without any delays. All patients are alive with no disease recurrence. The Bu‐Mel regimen is well tolerated and is feasible post‐COG‐type induction platform.
- 16 December 2013
- Published by Wiley in Pediatric Transplantation
- Vol. 18 (2) , E41-E43
Successful unrelated umbilical cord blood transplantation for class 3 β‐thalassemia major using a reduced‐toxicity regimen
Unrelated umbilical CB transplant for class 3 β‐thalassemia major is associated with an increased risk of mortality and non‐engraftment. We describe two patients who underwent successful unrelated umbilical CB transplant using a novel reduced‐toxicity preparative regimen. This regimen may be sufficiently immunosuppressive and myeloablative to ensure engraftment with reduced risks of toxicity and mortality. Close monitoring of HHV‐6 viral load is advised for patients undergoing transplant with this regimen.
- 16 December 2013
- Published by Wiley in Pediatric Transplantation
- Vol. 18 (2) , E41-E43
Successful unrelated umbilical cord blood transplantation for class 3 β‐thalassemia major using a reduced‐toxicity regimen
Unrelated umbilical CB transplant for class 3 β‐thalassemia major is associated with an increased risk of mortality and non‐engraftment. We describe two patients who underwent successful unrelated umbilical CB transplant using a novel reduced‐toxicity preparative regimen. This regimen may be sufficiently immunosuppressive and myeloablative to ensure engraftment with reduced risks of toxicity and mortality. Close monitoring of HHV‐6 viral load is advised for patients undergoing transplant with this regimen.